Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 58 • 2012 ACR/ARHP Annual Meeting
5 Million Patients and Not 0.34% Is Worrisome: Burden of Rheumatoid Arthritis in India Based On a Bone and Joint Decade India Community Oriented Program for Control of Rheumatic Disease
Arvind Chopra¹, R. Ghorpade², S. Sarmukkadam³, VL Joshi¹, AJ. Mathews⁴, L. Gauri⁵, A. Rahim⁶, K. Datta⁷, S. Chaturvedi⁸, B. Thakuria⁹, A. Mahajan¹⁰, R. Singh¹¹, A. Ghosh¹², R. Handa¹³, Manjit Saluja¹⁴, A. Venugopalan¹, V. Kunjeer¹, B. Paul⁶, S. Pal⁷, K. Wangjam¹¹, T. Kumar¹⁵ and K. Mahendranath¹⁶, ¹Rheumatology, Center for Rheumatic Diseases, Pune, India, ²Center for Rheumatic Diseases, Pune, India, ³BJMC, Pune, India, ⁴Government Medical College Hospital, Trivandrum, India, ⁵SP Medical College, Bikaner, India, ⁶Calicut Medical College, Calicut, India, ⁷Advance Rheumatology Clinic, Hyderabad, India, ⁸FRCH, Pune, India, ⁹Guwahati Medical College & Hospital, Guwahati, India, ¹⁰Government Medical College, Jammu, India, ¹¹Regional Institute of Medical Sciences, Imphal, Manipur, India, ¹²Rheumatology, Institute of Post Graduate Medical Education and Research, Kolkata, India, ¹³Department of Rheumatology, AIIMS, New Delhi, India, ¹⁴Clinical care, Center for Rheumatic Diseases, Pune, India, ¹⁵Institute of Post Graduate Medical Education and Research, Kolkata, India, ¹⁶Rheumatology Clinic, Bangalore, India
Background/Purpose : The 1 % prevalence of RA Worldwide is a deep rooted ancient dogma. None of the recent WHO ILAR COPCORD (Community Oriented Program…
Abstract Number: 2147 • 2012 ACR/ARHP Annual Meeting
Risks to Visit Emergency Room in Patients with Rheumatoid Arthritis: A Two-Year Retrospective Study
Yoshiki Nagai, Naoto Yokogawa, Kota Shimada and Shoji Sugii, Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) suffer from both physical disabilities and medical comorbidities and tend to use emergency room for many reasons. However, the…
Abstract Number: 1626 • 2012 ACR/ARHP Annual Meeting
Frequent Conversion of Tuberculosis Screening Tests During Anti-Tumor Necrosis Factor Therapy in Patients with Rheumatic Diseases
Chrisoula Hatzara¹, Emilia Hadziyannis², Anna Kandili¹, Stamatoula Tsikrika¹, Martha Minopetrou¹, Georgios Georgiopoulos¹ and Dimitrios Vassilopoulos¹, ¹2nd Department of Medicine, Athens University School of Medicine, Athens, Greece, ²2nd Department of Medicine and Laboratory of Clinical Immunology-Rheumatology, Hippokration General Hospital, University of Athens Medical School, Athens, Greece
Background/Purpose: The most recent ACR Recommendations suggest annual screening for latent tuberculosis (TB) with standard tuberculin skin test (TST) or the newer interferon-gamma release assays…
Abstract Number: 808 • 2012 ACR/ARHP Annual Meeting
Power Doppler Is Predictive of Treatment Failure in Early Rheumatoid Arthritis Patients: A One Year Follow-up Study
Karine R. Luz¹, Rita N.V. Furtado¹, Marcelo M. Pinheiro², Giovanna S. Petterle¹ and Jamil Natour¹, ¹Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil, ²Brazilian Registry of Spondyloarthritis, São Paulo, Brazil
Background/Purpose: It is known that ultrasound (US) is a useful test to monitor rheumatoid arthritis (RA) patients. However, to date, no study has shown the…
Abstract Number: 351 • 2012 ACR/ARHP Annual Meeting
Prospective Follow-up of Tocilizumab Treatment in 764 Patients with Refractory Rheumatoid Arthritis: Tolerance and Efficacy Data From the French Registry Regate (REGistry –RoAcTEmra)
Jacques Morel¹, Marie-Odile Duzanski², Thomas Bardin³, Alain G. Cantagrel⁴, Bernard Combe⁵, Maxime Dougados⁶, Rene-Marc Flipo⁷, Jacques-Eric Gottenberg⁸, Xavier Mariette⁹, Martin Soubrier¹⁰, Olivier Vittecoq¹¹, Alain Saraux¹², Thierry Schaeverbeke¹³ and Jean Sibilia¹⁴, ¹Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France, ²Service Pharmacie - Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ³Rheumatology, Hôpital Lariboisière, Paris, France, ⁴Dept of Rheumatology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France, ⁵Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁶Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ⁷Rheumatology, Hopital R Salengro CHRU, Lille, France, ⁸Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁹Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ¹⁰Rheumatology, CHU CLERMONT-FERRAND, Clermont-Ferrand, France, ¹¹Rheumatology, Rouen University Hospital & Inserm905, University of Rouen, Rouen Cedex, France, ¹²Rhumatologie, CHU de la Cavale Blanche, Brest Cedex, France, ¹³Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ¹⁴Rhumatologie, CHU Hautepierre, Strasbourg, France
Background/Purpose: To assess tolerance and safety of rheumatoid arthritis (RA) treatment by tocilizumab (TCZ) in real life Methods: The French Society of Rheumatology and the…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].